Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Posted by Steven Smith on Nov 7th, 2024

Cellectis (NASDAQ:CLLS – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03), Zacks reports. The firm had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. During the same quarter in the prior year, the business posted ($0.31) earnings per share.

Cellectis Stock Performance

Cellectis stock traded down $0.03 during mid-day trading on Thursday, reaching $1.74. 30,755 shares of the company’s stock were exchanged, compared to its average volume of 48,739. The business’s fifty day simple moving average is $2.07 and its 200 day simple moving average is $2.27. The firm has a market capitalization of $96.72 million, a PE ratio of -1.35 and a beta of 3.10. Cellectis has a one year low of $1.73 and a one year high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39.

Analyst Ratings Changes

Several equities analysts have commented on CLLS shares. Barclays dropped their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday. StockNews.com initiated coverage on Cellectis in a research report on Tuesday. They issued a “sell” rating for the company.

Get Our Latest Stock Analysis on CLLS

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.